Hatch softens stance on Biologics, wants TPP to pass

orrin_hatch_defends_park51.jpg

[ Daily News| September 08, 2016 | Inside US Trade]

Senate Finance Committee Chairman Orrin Hatch (R-UT) this week said commitments from Trans-Pacific Partnership countries on his demand for 12 years of market exclusivity for biologic drugs would not have to be framed in a contract or a side agreement – but rather as a “methodology” he believes “honorable” countries will follow.

“We have to come up with a methodology where they agree to 12 years,” Hatch told Inside U.S. Trade on Sept. 7. “That doesn't have to be a contract; it doesn't have to be an agreement; there are a number of ways they can do that. And honorable countries will live up to it.”

Hatch said his “specific demand” can be achieved by “finding a way of having the countries agree to change that terminology in the TPP to 12 years, or come up with something that would be acceptable.”

Read more at Inside US Trade

Sign in or create an account below to post your comment

Please check your e-mail for a link to activate your account.